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Graded doses of Nature Cure Bitters (NCB) were administered daily (100, 200 and 400 mg/kg p.o) to rats 
for 28 days and the effects on body weight, organ weight, clinical signs, gross pathology, haematology, 
histology and serum biochemical parameters were evaluated. The relative weights of the heart, liver and 
testes of treated rats were unaffected in contrast to a significant increase in the relative weights of the 
lungs, kidneys and spleen. The packed cell volume and haemoglobin concentrations were significantly 
reduced whereas total leucocyte counts and glucose levels were remarkably increased. A significant 
decrease in alkaline phosphatase occurred in all the groups but alanine aminotransferase and albumin 
levels were significantly elevated. NCB elicited hypo-cholesterolaemic effects in addition to lowering 
urea, uric acid, BUN and total protein concentrations. Histological findings did not reveal any treatment-
related effects. The calculated therapeutic index was >37.5. These preliminary results suggest that NCB 
was not likely to produce severe toxicological effects on organ weights, haematological and biochemical 
indices when given at normal therapeutic doses. 
 





Herbal prescriptions and natural remedies are commonly 
employed in developing countries for the treatment of 
various diseases, this practice being an alternative way to 
compensate for some perceived deficiencies in orthodox 
pharmacotherapy (Sofowora, 1989; Zhu, 2002). 
Unfortunately, there is limited scientif ic evidence 
regarding safety and efficacy to back up the continued 
therapeutic application of these remedies. The rationale 
for their utilisation has rested largely on long-term clinical 
experience (Zhu, 2002). But now, with the upsurge in the 
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tion of these plants will go a long way in validating their 
folkloric usage (Sofowora, 1989).  
Nature Cure Bitters (NCB) is one of such polyherbal 
formulations used for various ethnomedicinal purposes in 
Nigeria. The constituents of Nature Cure Bitters include 
Hilleria latifolia H. Walt (Phytolaccaceae), Citrus 
aurantifolia Swingle (Rutaceae) and Xylopia aethiopica A 
Rich (Anonaceae) (Table 1). Ethnomedicinally, 140 mls of 
the liquid product (80 mg/kg/day) is taken daily in two 
divided doses for seven days for the treatment of liver 
cirrhosis, kidney failure, diabetes mellitus, waist pain, 
arthritis, rheumatism, infertility problems as well as 
typhoid fever and haemorrhoids. It is also given for the 
relief of menstrual pain, convulsions, constipation and 
stomach-ache (Nwaneri, Nwaneri Botanic Centre Ltd., 
Enugu, Nigeria, Personal Communication).   
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                                                 Table 1. Approximate percentage composition of nature cure bitters (g/100 ml). 
 
Component Family Quantity Used (%) 
Hilleria latifolia (root)  Phytolaccaceae 15 
Citrus aurantifolia (fruit)  Rutaceae 10 
Xylopia aethiopica (root) Anonaceae 0.8 





The medicinal uses of Hilleria latifolia, Citrus 
aurantifolia Xylopia aethiopica are well documented in the 
literature (Dalziel, 1937).  But to our knowledge, there is 
yet no record in the literature of the toxicity profile of all 
these plants used in combination. Such sub-acute or sub-
chronic toxicity data may be required to predict the safety 
or otherwise of long term low dose exposure to a 
particular medicinal product (McNamara, 1976). 
The present investigations were therefore carried out in 
our laboratory to determine the acute and sub-acute 
toxicity profile of NCB in rodents. 
 
 
MATERIALS AND METHODS 
 
Test Material  
 
Nature Cure Bitters was supplied by Dr. E. P. C. Nwaneri, Nwaneri 
Botanic Centre Ltd., Enugu, Nigeria as a liquid formulation. The 
material was stored in a refrigerator at 4°C and protected from light 
until time of drug administration when it was allowed to warm up to 
room temperature. Upon the attainment of room temperature (27 ± 
2°C), the appropriate volumes of the preparation were administered 





Adult Wistar rats (180 – 240 g) and Swiss albino mice (20 – 30 g) of 
either sex were used for the acute toxicity studies. But only male 
rats (200 -250 g) were used for the sub-acute toxicity profiling. The 
animals were supplied by the Animal Facility Centre (AFC), National 
Institute for Pharmaceutical Research and Development (NIPRD), 
Abuja, Nigeria. They were fed ad libitum with standard feed 
(Ladokun Feeds, Ibadan, Nigeria) and had free access to water 
(Abuja Municipal water supply). They were also maintained under 
standard conditions of humidity, temperature and 12 h 
light/darkness cycle. The animals were acclimatised for a week 
before the commencement of the study. A standard protocol was 
drawn up in accordance with the Good Laboratory Practice (GLP) 
Regulations of the WHO (1998). The “principles of laboratory animal 






Kits for glutamate oxaloacetate transaminase (GOT, AST), 
glutamate pyruvate transaminase (GPT, ALT), alkaline phosphatase 
(ALP), total proteins, albumin, total bilirubin, glucose, urea, uric acid, 
Blood Urea Nitrogen (BUN), total cholesterol and triglycerides used  
 
 
for the biochemical studies were supplied by Human Gesellschaft 
für Biochemica and Diagnostica MBH, Germany. 
 
 
Acute toxicity studies 
 
The acute toxicity (LD50) was estimated i.p. and p.o. in mice and 
rats (n = 17 in each case) following Lorke’s method (1983). Dose 
levels used ranged from 500 to 3000 mg/kg. The number of deaths 
in each group within 24 h (for i.p.) or 72 h (for p.o.) was recorded. 
The acute toxicity LD50 was calculated as the geometric mean of the 
dose that resulted in 100% mortality and that which caused no 
lethality at all. If any inconsistencies were observed in the mortality 




Sub-acute toxicity studies 
 
Twenty four (24) rats were selected by stratified randomisation and 
then divided into four groups of six each. The first group served as 
control while the remaining three groups were given 100, 200 and 
400 mg/kg of Nature Cure Bitters orally for 28 days. The first day of 
dosing was taken as D0 whereas the day of sacrifice was 
designated as D28.  
 
 
Weekly body weight 
 
The body weight of each rat was assessed using a sensitive 
balance during the acclimatization period, once before 
commencement of dosing, once weekly during the dosing period 
and once on the day of sacrifice. 
 
 
Mortality and clinical signs 
 
During the four-week dosing period, all the animals were observed 
daily for clinical signs and mortality patterns once before dosing, 
immediately after dosing and up to 4 h after dosing. 
 
 
Relative Organ Weight 
 
On day 28 of the dosing period, all the animals were euthanised by 
exsanguination under chloroform anesthesia. Different organs 
namely the heart, liver, lungs, spleen, kidneys and testes were 
carefully dissected out and weighed in grams (absolute organ 
weight). The relative organ weight of each animal was then 
calculated as follows: 
 
                                               Absolute organ weight (g) 
RelativeOrgan Weight   =                                                         X 100                 
                                       Body weight of rat on sacrifice day (g)    
 
































Figure 1. Mean Body Weight Changes in Rats fed Nature Cure 
Bitters for 28 days. The control rats gained weight throughout the 
duration of treatment whereas weight loss was observed in rats fed 
100 and 400 mg/kg of NCB. The 200 mg/kg group also gained 
weight in a manner similar to that of the control rats. However, 




Gross pathology and microscopic examination 
 
Dead animals were weighed and necropsied soon after death (or as 
soon as possible if death occurred overnight) and macroscopic 
examination of the organs carried out. Tissue biopsies from the 
heart, liver, kidneys, lungs, spleen and testes were fixed in 10% 
formal saline. These were processed with an automatic tissue 
processor (Shandon Citadel Model 2000). Following dehydration 
and embedding, sections were cut at 4-5 µ with the rotary 
microtone, stained with hematoxylin and eosin and examined 
microscopically. Additional thin sections of the kidneys were cut at 3 






The packed cell volume (PCV) and haemoglobin (Hb) estimation 
were carried out using the microhaematocrit and 
cyanmethanemoglobin methods of Baker and Silverton (1985). The 
methods of Baker and Silverton (1985) and Jain (1986) were 
employed to determine the total leucocyte counts (TLC) whereas 
the longitudinal method of Baker and Silverton (1985) provided a 
good assay for the differential leucocyte Count (DLC). 
 
 
Preparation of sera samples   
 
On Day 28 of the dosing period, all the animals were exsanguinated 
under chloroform anaesthesia and blood samples were drawn from 
the heart of each sacrificed animal. The samples were collected in 






clotting. The clotted blood samples were centrifuged at 3000 rpm for  






The following parameters were determined colorimetrically by 
employing the standard ready-to-use kits and methods of Human 
(Human Gesellschaft für Biochemica and Diagnostica MBH, 
Germany): Glutamate oxaloacetate transaminase (GOT, AST), 
glutamate pyruvate transaminase (GPT, ALT), alkaline phosphatase 
(ALP), total proteins, albumin, total bilirubin, glucose, urea, blood 
urea nitrogen (BUN), uric acid, total cholesterol and triglycerides. 
The manufacturer's instructions for each biochemical parameter 





The results are expressed as means ± standard error of the mean 
(SEM). Some of the data were analysed as a completely 
randomised design using one-way analysis of variance (ANOVA) 
whereas the remaining results were amenable to two-way ANOVA  
(Petersen, 1985; Scheffe, 1993). Any significant difference between 
means was assessed by both the Student’s t-test and Dunnett’s 
post hoc test (Dunnett, 1993). 95% level of significance (P < 0.05) 





Acute toxicity studies 
 
At the dose levels tested, no untoward clinical signs were 
observed in the surviving mice and rats. There were no 
changes in the nature of stool, urine and eye colour of all 
the animals. No mortality was observed in the different 
groups of mice and rats that received NCB orally after 72 
h. 100% mortality occurred in mice that were given 1600 
mg/kg of NCB i.p whereas no lethality was observed in 
those given 1200 mg/kg (i.p) after 24 h.  In rats, i.p 
administration of NCB produced no deaths at 1600 mg/kg 
post 24 h.  Similarly, 3000 mg/kg of NCB was well 
tolerated in rats even after 72 h. Hence the LD50 values 
were estimated to be as follows: Rats: > 1600 mg/kg (i.p) 
and > 3000 mg/kg (p.o);  Mice:  1,386 mg/kg (i.p) and  > 
2,500 mg/kg (p.o). 
 
 
Weekly body weight 
 
From D0 to D28, there were variable changes in the body 
weight of rats in all the groups. The control rats gained 
weight throughout the duration of treatment whereas 
weight loss was observed in rats fed 100 and 400 mg/kg 
of NCB. Surprisingly, the 200mg/kg group also gained 
weight in a similar fashion as the control rats. However, 
these changes in the body weights of treated rats were  
 








Heart Lungs Liver Spleen Kidneys Testes 
Control  0.3±0.06 0.72± 0.02 3.88± 0.24 0.42 ±0.10 0.63 ± 0.08 2.49± 0.02 
NCB (100) 0.41± 0.03 0.89±0.07* 3.75± 0.12 0.46 ±0.03 0.73±0.03 2.35 ±0.07 
NCB (200) 0.43± 0.07 0.91± 0.09* 3.46± 0.16 0.52± 0.10 0.69 ± 0.03 2.20 ±0.11 
NCB (400) 0.45± 0.05 0.83± 0.06 4.3 ± 0.13 0.76±0.07* 0.89 ±0.05* 2.51±0.09 
 
       NCB = Nature Cure Bitters, n = 6, 





                                 Table 3. Haematological profile in male rats given 100-400mg/kg of NCB for 28 days. 
 
DLC (%) Treatment  
(mg/kg/day) 
PCV (%) Hb (g/dL) TLC  (X 109/L) 
N L 
Control 40.0 ± 1.2 13.7  ±  0.4 3.8  ±  0.5 31.0  ± 2.5 69.0 ± 2.5 
NCB (100) 34.5  ±  0.7* 11.8  ±  0.2* 7.0 ±  0.7* 33.5  ± 3.2 66.5 ± 3.2 
NCB (200) 39.0  ±  1.6 13.4  ±  0.5 9.70  ± 2.2* 31.3  ± 4.8 68.7 ±  4.8 
NCB (400) 33.0  ±  1.1* 11.3 ± 0.3* 12.60  ± 3.4* 38.0  ± 5.1 62.0  ± 5.1 
 
PCV = Packed cell volume, Hb = Haemoglobin concentration 
TLC = Total leucocyte count, DLC = Differential leucocyte counts 
N = Neutrophils, L = Lymphocytes, n = 6  




not significantly different from control (Figure 1). 
 
 
Clinical signs and mortality patterns 
 
During the four weeks of treatment, dose-dependent 
mortalities of 16.7, 33.4 and 50% occurred in the 100, 
200 and 400 mg/kg groups respectively. Mild sedative 
effects were clearly perceptible but no other adverse 
clinical manifestations (e.g. diarrhoea, haematuria, 
restlessness, unco-ordinated muscle movements etc) 
were seen in the experimental animals during the dosing 




Relative organ weight 
 
There were no significant changes in the relative weights 
of the heart, liver and testes of treated rats in relation to 
control groups. However, 100 and 200 mg/kg of NCB 
produced a significant increase in the relative weight of 
the lungs. At 400 mg/kg, a significant increase in the 
spleen and kidney weights occurred but the elevations at 
100 and 200 mg/kg were not statistically remarkable   
(Table 2). 
Gross and histological pathology 
 
No treatment-related gross pathological changes were 
found in the heart, liver, lungs, spleen, kidneys, and 
testes of the rats at the dose levels tested. The incidence 
Fof histopathogical findings was similar in both control 





The packed cell volume (PCV) and haemoglobin 
concentrations (Hb) were reduced at all the dose levels 
tested and these reductions were significantly different 
from control at 100 and 400 mg/kg. Similarly, there was a 
significant, dose-dependent increase in the total 
leucocyte count (TLC) in all the groups. No significant 
effects were observed in the differential leucocyte counts 
at the experimental doses (Table 3). 
 
 
Effects on hepatic function indices 
 
The effects of Nature Cure Bitters on liver function indices 
are presented in Table 4. The alkaline phosphatase (ALP)  








AST  (IU/L) ALT (IU/L) ALP (IU/L) T.BIL (µmol/L) ALB (g/dL) Glu (mg/dl) T. PROT 
(g/dL) 
Control  179  ±  17 93 ± 16 601 ± 56 5.0 ± 1.0 5.8 ±  0.6 87  ± 5 10.2 ± 2.5 
NCB (100) 226  ±  28 114 ± 14 359 ± 66* 5.8  ±  0.9 8.0  ±  1.1 119  ±   11* 8.3 ±  0.2 
NCB (200) 149 ± 7 121  ±  11 364 ± 46* 3.7 ± 2.9 6.8 ±  0.6 152  ± 26* 8.6 ±  1.8 
NCB (400) 220 ± 19 168  ± 15* 406 ± 54* 4.5 ± 1.3 8. ± 0.7* 199 ±  48* 6.2 ± 0.5 
 
 
AST = Aspartate Aminotransferase, ALT = Alanine Aminotransferase 
ALP = Alkaline Phosphatase, T.BIL = Total Bilirubin 
ALB = Albumin, Glu = Glucose, T.PROT = Total Proteins ;  





and total protein levels were decreased at all the dose 
levels tested although this decrease did not appear to be 
dose-dependent. While the decrease in total protein 
levels was not significantly different from control, that of 
ALP was significant at all the dose levels tested. 
There was a dose dependent increase in serum ALT 
concentration, this elevation being significant at only 400 
mg/kg. Similarly, albumin levels were apparently 
increased at all the dose levels tested and this effect was 
remarkable at 400 mg/kg. Variable but non-significant 
responses were obtained in the serum AST and total 
bilirubin concentrations. Total bilirubin levels increased 
initially at 100 mg/kg but were subsequently reduced at 
200 and 400 mg/kg whereas AST concentrations 
increased at 100 and 400 mg/kg with a reduction 
occurring only at 200 mg/kg. NCB caused a significant, 
dose-dependent increase in serum glucose levels at all 
the doses tested.  
 
 
Effects on renal function parameters 
 
Once daily administration of Nature Cure Bitters for four 
weeks resulted in decreased levels of urea, uric acid and 
blood urea nitrogen (BUN) at all the dose levels tested. 
The reduction in uric acid was statistically significant at 
100 and 400 mg/kg (Table 3). 
 
 
Effects on serum lipid profile 
 
Serum triglyceride concentrations were decreased dose-
dependently at 100 and 200 g/kg whereas at 400 mg/kg, 
an elevation occurred. The decrease at 200 mg/kg was 
remarkably different from control. On the other hand, NCB 
caused a dose-dependent decrease in total cholesterol 
levels. This hypocholesterolaemic effect of NCB in rats 




Even though the acute toxicity (LD50) test has been widely 
criticized as a parameter for assessing toxicity (Lorke, 
1983; Klaasen, 2001; Timbrel, 2002), there are still 
certain occasions when some useful information could be 
obtained from such studies. Apart from giving a clue on 
the range of doses that could be used in subsequent 
toxicity testing, it could equally reveal the possible clinical 
signs elicited by the substance under investigation. It’s 
also a useful parameter for estimating the Therapeutic 
Index (ie LD50 / ED50) of drugs and xenobiotics (Rang et 
al., 2001). 
The present study has shown that NCB possesses 
fairly high oral LD50 values (> 2500 and > 3000 mg/kg in 
mice and rats, respectively) in relation to its folkloric 
therapeutic dose (80 mg/kg/day). Thus its high oral 
Therapeutic Index (> 37.5) might be used as a rough 
indication of a wide margin between the effective and 
toxic doses. 
But such acute toxicity data are of limited clinical 
application since cumulative toxic effects do occur even 
at very low doses. Hence sub-acute and chronic toxicity 
studies are almost always invaluable in evaluating the 
safety profile of phytomedicines. This probably explains 
why some authors have suggested that sub-chronic 
toxicity data may be needed to predict the hazard of long-
term, low-dose exposure to a particular compound 
(McNamara, 1976). 
The high mortality rate obtained at 400 mg/kg is 
probably an indication that this dose level is too toxic to 
the experimental animals. But 400 mg/kg is about five 
times the therapeutic dose and this high dose is rarely 
used ethnomedicinally. This may be an important point in 
assessing the suitability of NCB for therapeutic use 
(Gathumbi et al., 2002). 
Ordinarily, liver cell damage is characterized by a rise 
in plasma enzymes (AST, ALT, LDH etc). From our 






than ALT levels which are expected since body cells 
contain more AST than ALT (Mayne, 1996). Usually, 
about 80% of AST is found in the mitochondria whereas 
ALT is a purely cytosolic enzyme. Therefore, AST 
appears in higher concentrations in a number of tissues 
(liver, kidneys, heart and pancreas) and is released slowly 
in comparison to ALT. But since ALT is localized primarily 
in the cytosol of hepatocytes, this enzyme is considered a 
more sensitive marker of hepatocellular damage than 
AST and within limits can provide a quantitative 
assessment of the degree of damage sustained by the 
liver (Al-Mamary et al., 2002). Therefore, the significant 
elevation in ALT level at 400 mg/kg could be an indication 
of hepatocellular changes induced by NCB. Surprisingly, 
the liver histology did not reveal any evidence of 
centrilobular degenerative changes, steatosis or necrosis 
at this dose level. Indeed microscopic examination of the 
selected organs did not reveal any treatment-related 
effects showing that the observed elevations in some 
biochemical parameters might actually be artefactual in 
nature (Salazar et al., 1998). This view is also 
strengthened by the fact that the relative weights of the 
liver, heart and testes did not show any evidence of 
toxicity. 
The significant reduction in ALP levels by NCB shows 
that no possible cholestasis occurred at the dose levels 
tested since a rise in plasma alkaline phosphatase (ALP) 
level is usually a characteristic finding in cholestatic liver 
disease (Kaneko, 1989). This was further confirmed by 
the fact that at 200 and 400 mg/kg, significant 
hypobilirubinaemic effects were observed, testifying 
possibly that the hepatic capacity to excrete bilirubin was 
not impaired by NCB (Mayne, 1996). 
The significant increase in serum glucose levels in 
treated rats shows that NCB could produce some 
hyperglycaemic effects. Hence caution and close 
monitoring of glucose levels might be necessary when 
patients are placed on this herbal remedy. The increased 
albumin levels (hyperalbuminaemic effect) were probably 
secondary to hypoproteinaemia indicating that the 
synthetic function of the liver might not have been 
tampered with (Mayne, 1996). 
On serum lipid profile, the dose-dependent reductions 
in serum triglyceride and total cholesterol concentrations 
is a positive attribute of NCB and might just be a 
revelation of the potentials of this herbal formula as a 
lipid-lowering drug in mixed hyperlipidaemic states. The 
observed dose-dependent hypocholesterolaemic effect 
may be important because of the salient relationship that 
exists between serum cholesterol levels and the 
incidence of Ischaemic and coronary heart diseases such 
as atherosclerosis (Stamler, 1986; Dixit et al., 2000). 
The reduced levels of urea, uric acid and BUN 
probably indicate that NCB did not interfere with the renal 
capacity to excrete these metabolites. It may also be a 
reflection of the preserved  renal  integrity  of  treated  rats  
 




(Kaneko, 1989).  
In addition, the diets were well accepted by the treated 
rats suggesting that NCB did not possibly cause any 
alterations in carbohydrate, protein or fat metabolism in 
these experimental animals. It also shows that NCB did 
not adversely interfere with the nutritional benefits (e.g. 
weight gain, stability of appetite) expected of animals that 
are continually supplied with food and water ad libitum.  
100 and 200 mg/kg of NCB produced a significant 
increase in the relative weight of the lungs, thus revealing 
the possible toxic effects of NCB to the lungs.  In an 
analogous manner, the spleen and kidneys were 
adversely affected judging by the significant increase in 
their relative weights at 400 mg/kg. Predictably, the PCV 
and Hb levels were reduced in treated rats indicating that 
NCB could produce some anaemic effects. How 
applicable this observation could be to humans remains 
an issue yet to be investigated. But if such results are 
extrapolable to man, then in the case of sickle cell 
anaemia patients, long-term exposure to this drug might 
precipitate a crisis situation (Sofowora, 1989).  
The dose-dependent elevations in total leucocyte 
counts (TLC) could be an attestation of the fact that NCB 
may contain biologically active principles that have the 
ability to boost the immune system through increasing the 
population of defensive white blood cells. The reduction in 
lymphocyte count was compensated by an increased 
neutrophil count suggesting that NCB may possess some 
anti-lymphocytic activity (Garg et al., 1997). 
The present investigations could be regarded as 
preliminary probes, necessitating further studies to 
establish the mechanisms of toxicity of NCB. Prospective 
studies should include amongst other things a battery of 
reproductive toxicity, genetic toxicity, mutagenicity and 
carcinogenicity tests in addition to effects on drug 
metabolising enzymes (especially cytochrome P-450s) 
and toxicokinetic profiling. When such data are available, 
a conclusive remark can then be made on the safety 
profile of NCB. 
Nevertheless, the present findings have shown that 
NCB is not likely to produce severe toxicological effects 
on organ weights, haematological and biochemical 
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